Literature DB >> 23933656

Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia.

H S Lindgren1, D Rylander, H Iderberg, M Andersson, S S O'Sullivan, D R Williams, A J Lees, M A Cenci.   

Abstract

The transcription factor ΔFosB is a mediator of maladaptive neuroplasticity in animal models of Parkinson's disease (PD) and L-DOPA-induced dyskinesia. Using an antibody that recognizes all known isoforms of FosB and ΔFosB, we have examined the expression of these proteins in post-mortem basal ganglia sections from PD patients. The patient cases were classified as being dyskinetic or non-dyskinetic based on their clinical records. Sections from neurologically healthy controls were also included in the study. Compared to both controls and non-dyskinetic cases, the dyskinetic group showed a higher density of FosB/ΔFosB-immunopositive cells in the posterior putamen, which represents the motor region of the striatum in primates. In contrast, the number of FosB/ΔFosB-positive cells did not differ significantly among the groups in the caudate, a region primarily involved with the processing of cognitive and limbic-related information. Only sparse FosB/ΔFosB immunoreactivity was found in the in the pallidum externum and internum, and no significant group differences were detected in these nuclei. The putaminal elevation of FosB/ΔFosB-like immunoreactivity in patients who had been affected by L-DOPA-induced dyskinesia is consistent with results from both rat and non-human primate models of this movement disorder. The present findings support the hypothesis of an involvement of ΔFosB-related transcription factors in the molecular mechanisms of L-DOPA-induced dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 23933656     DOI: 10.3233/JPD-2011-11068

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  13 in total

1.  Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.

Authors:  Lisa F Potts; Eun S Park; Jong-Min Woo; Bhagya L Dyavar Shetty; Arun Singh; Steven P Braithwaite; Michael Voronkov; Stella M Papa; M Maral Mouradian
Journal:  Ann Neurol       Date:  2015-03-27       Impact factor: 10.422

2.  Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.

Authors:  Kathy Steece-Collier; Timothy J Collier; Jack W Lipton; Jennifer A Stancati; Mary E Winn; Allyson Cole-Strauss; Rhyomi Sellnow; Melissa M Conti; Natosha M Mercado; Eduardo A Nillni; Caryl E Sortwell; Fredric P Manfredsson; Christopher Bishop
Journal:  Exp Neurol       Date:  2020-05-05       Impact factor: 5.330

3.  Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.

Authors:  José-Rubén García-Montes; Oscar Solís; Juan Enríquez-Traba; Irene Ruiz-DeDiego; René Drucker-Colín; Rosario Moratalla
Journal:  Mol Neurobiol       Date:  2018-09-27       Impact factor: 5.590

4.  A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.

Authors:  Michael Feyder; Erik Södersten; Emanuela Santini; Vincent Vialou; Quincey LaPlant; Emily L Watts; Giada Spigolon; Klaus Hansen; Jocelyne Caboche; Eric J Nestler; Gilberto Fisone
Journal:  Biol Psychiatry       Date:  2014-07-28       Impact factor: 13.382

Review 5.  Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.

Authors:  M Angela Cenci
Journal:  Front Neurol       Date:  2014-12-15       Impact factor: 4.003

Review 6.  Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?

Authors:  Daniella Rylander Ottosson; Emma Lane
Journal:  Front Cell Neurosci       Date:  2016-02-08       Impact factor: 5.505

Review 7.  On the neuronal circuitry mediating L-DOPA-induced dyskinesia.

Authors:  M Angela Cenci; Henrik Jörntell; Per Petersson
Journal:  J Neural Transm (Vienna)       Date:  2018-04-27       Impact factor: 3.575

Review 8.  Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment.

Authors:  Yixuan Liang; Li Cui; Jiguo Gao; Mingqin Zhu; Ying Zhang; Hong-Liang Zhang
Journal:  Mol Neurobiol       Date:  2021-04-06       Impact factor: 5.590

9.  Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.

Authors:  T Fieblinger; L Zanetti; I Sebastianutto; L S Breger; L Quintino; M Lockowandt; C Lundberg; M A Cenci
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

Review 10.  Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.

Authors:  Giada Spigolon; Gilberto Fisone
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.